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Idiopathic pulmonary fibrosis (IPF) is a debilitating condition with life expectancy of two to five
years from diagnosis. Treatment strategies for IPF are disappointingly limited and pirfenidone
is currently the only licensed drug that has been shown to reduce the decline in forced vital
capacity (FVC) at six months. We demonstrate our experience in prescribing pirfenidone in a
single centre observational study of forty patients involved in a named patient programme
(NPP) from September 2011 to January 2013.
We demonstrate that improved adherence and compliance can be achieved by specialist
nurse and clinician review, support and education of the patient. Twenty three of 40 (58%) pa-
tients experienced predominantly gastrointestinal adverse effects. Importantly we have
enhanced patient adherence and compliance from an initial discontinuation rate of six pa-
tients (15%) at the beginning of the study to a zero discontinuation rate in the subsequent
ten months.
This study shows that in the real world pirfenidone is well tolerated and with expert regular
specialist review adherence can be optimised and improved.
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Idiopathic pulmonary fibrosis (IPF) is a debilitating condi-
tion with life expectancy of two to five years from diag-
nosis. Treatment strategies for IPF are disappointingly
limited and pirfenidone is currently the only licensed drug
that has been shown to reduce the decline in forced vital
capacity (FVC) at six months [1]. In the United Kingdom
pirfenidone has undergone National Institute of Health and
Clinical Excellence (NICE) consultation for approval in its
use for patients with IPF. Pirfenidone is currently only
prescribed in selected specialist centres on a named pa-
tient programme (NPP).Methods
This was a single centre observational study of patients
involved in the NPP. Inclusion criteria included a multidis-
ciplinary team (MDT) diagnosis of IPF as per American
Thoracic Society/European Respiratory Society (ATS/ERS)
criteria [2], FVC greater than 50% and/or carbon monoxide
diffusing capacity (DLCO) greater than 35% predicted.
Patients consented to the NPP. All patients had baseline
pulmonary function tests (PFTs), full blood count (FBC) and
liver function tests (LFTs) prior to commencing pirfenidone.
Pirfenidone was prescribed as per manufacturer’s recom-
mendations. Patients were reviewed at monthly intervals
for the first six months, and then three monthly thereafter,
if stabilised on treatment. Each clinical review involved
confirmation of the dose of pirfenidone, any side effects in
the preceding months, chest infections, hospital admissions
and new medication. FBC and LFTs were checked at each
clinical review. PFTs were performed at baseline and three
monthly intervals after treatment commencement. In some
patients we had pre-pirfenidone PFTs which gave us the
opportunity to compare decline in FVC and DLCO pre- and
post-commencement of pirfenidone in a limited numbers of
patients.
We retrospectively analysed the data from forty patients
treated with pirfenidone from September 2011 to January
2013. Data were analysed using GraphPad Prism v5. Where
indicated data was compared using unpaired two tailed t-
tests.Figure 1 There appears to be a reduction in FVC and DLCO
decline after commencement of pirfenidone. Pulmonary
function tests were performed at three, six and nine months
pre- and post-pirfenidone commencement. The percentage
change in FVC and DLCO was calculated from baseline values at
commencement of pirfenidone. Data shown are mean  SEM at
three, six and nine months pre- and post-pirfenidone
commencement (n Z 14, 14 and 11 pre-pirfenidone and
n Z 26, 23 and 15 post-pirfenidone respectively). The gradi-
ents of the slopes were calculated using linear regression
analysis using Prismv5 software.Results
At commencement of pirfenidone the mean age was 65.8
years (range 48e80) with 70% males. Average baseline FVC
and DLCO was 77.3% (range 46e146%) and 42.4% (range
14e81%) respectively. Fifteen (37.5%) patients had an FVC
greater than 50% with baseline DLCO of less than 35%. Seven
(18%) patients were receiving long term oxygen therapy,
four (10%) had ambulatory oxygen and 29 (72%) received no
oxygen. At commencement of pirfenidone seven (17%), five
(12%) and nine (23%) patients were taking prednisolone
(average 10 mg), N-acetylcysteine (NAC) or both predniso-
lone and NAC respectively. During this time period twelve
(30%) patients died, of which 9 (75%) had a baseline DLCO of
less than 35%. Ten patients died due to progression of their
IPF, one due to a diagnosis of lung cancer and one due toexacerbations. These patients had significantly reduced
duration of treatment (18.4  2.4 vs. 42.3  4.7 weeks
p Z 0.0017) and severer disease as measured by baseline
DLCO compared to survivors (30.2  2.2% vs. 48.1  2.9%
p Z 0.0002). A total of 21 (52%) patients continued treat-
ment to the end of the study period and six (15%) dis-
continued treatment due to adverse effects.
Twenty three of 40 (58%) patients experienced adverse
effects. Twelve (52%) patients experienced one adverse
effect, seven (31%) experienced two and four (17%) pa-
tients experienced three or more adverse effects. The
majority of adverse effects were gastrointestinal in nature
(87%). Other adverse effects included exacerbations of IPF
(12.8%), rash (10.3%) and pneumothorax (2.6%) Adverse
effects occurred within an average of 8.1 weeks (range
1.5e34) and in those patients with lower body mass index
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adverse effects nine (39%) were self-limiting and resolved
with simple measures. Three (13%) resolved after a reduc-
tion in dosage, in three (13%) patients pirfenidone was
restarted after the adverse effect settled and two (9%)
patients died due to their exacerbation. Only four patients
experienced mild abnormalities in LFTs that resolved
spontaneously on repeated testing without any alteration
of medication. Despite similar incidence of adverse effects,
patients with DLCO of less than 35% were less likely to
continue treatment (29% vs. 71%) and more likely to dis-
continue treatment due to their adverse effects (67% vs.
33%).
During the first six months of recruitment six (15%) pa-
tients discontinued treatment due to adverse effects. In
the later ten months we had no discontinuations. This has
been attributed to a number of factors. Patient factors
included simple measures such as use of sun protection and
taking the pirfenidone capsules at the start, middle and
end of a meal in an attempt to minimise side effects. We
found that the majority of adverse effects occurred within
the first eight weeks of treatment and as a result monthly
specialist nurse review for the first three months, to assess
and reinforce adverse effect avoidance measures was, we
feel, paramount to the success of our increased adherence.
Patients were also given a contact number and encouraged
to speak to a specialist nurse if they experienced any
adverse effects. This allowed us to act promptly and either
reduce, temporarily discontinue or administer further
medication in order to alleviate the adverse effects.
At six and nine months before and after pirfenidone
commencement we observed a reduction in the decline of
mean percentage change of FVC and DLCO at start of
treatment. At nine months there was a difference in
gradient of decline before and after pirfenidone
commencement of 1.043  1.605 vs. 0.197  0.231 for
FVC decline and 1.427  1.568 vs. 0.1  0.367 for DLCO
decline (Fig. 1).
Conclusion
Our data regarding reduction in decline of FVC and DLCO is
encouraging and may support the previous efficacy data
from clinical trials. However, we acknowledge the majorlimitations of drawing any statistical conclusions from this
retrospective observational data with small patient
numbers, lack of appropriate controls and incomplete
pulmonary function data. We demonstrate that, compared
to patients with less severe disease, patients with a
DLCO < 35% are more likely to discontinue treatment
despite a similar incidence of adverse effects, presumably
due to a lack of beneficial effect on symptoms. We believe
that regular specialist nurse support, advice and education,
particularly in the first months of treatment when adverse
effects are likely to occur, is paramount to the optimal
adherence and compliance of pirfenidone.
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